Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FKKF5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,474
Award facts
- Contract value 100% obligated
- $17,474.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $17,474.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector units. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of December 31, 2025, and no set-aside designation was utilized. DMS Pharmaceutical Group will fulfill this order from its Park Ridge location and deliver the immunosuppressant biologic medication to support Department of Defense healthcare operations.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical and medical supply support to military healthcare facilities worldwide. The parent IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. DMS Pharmaceutical Group's established performance across multiple therapeutic categories, including specialty biologics, oncology treatments, vaccines, and emergency medications, positions the company as a critical supplier within the federal pharmaceutical supply chain for Department of Defense medical operations.
Quick answers
Who was awarded contract SPE2DR26FKKF5?
SPE2DR26FKKF5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 9, 2025.
How much is contract SPE2DR26FKKF5 worth?
The government has obligated $17,474 on SPE2DR26FKKF5.
Is contract SPE2DR26FKKF5 an order under another contract?
Yes. SPE2DR26FKKF5 is a delivery order under SPE2DR25D9367, an indefinite delivery contract.
Was contract SPE2DR26FKKF5 competed?
The extent of competition for SPE2DR26FKKF5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award